TY - JOUR
T1 - Nonalcoholic fatty liver disease and risk of diabetes
T2 - A prospective study in China
AU - Shen, Xiuhua
AU - Cai, Jianfang
AU - Gao, Jingsheng
AU - Vaidya, Anand
AU - Liu, Xuemei
AU - Li, Wen
AU - Chen, Shuohua
AU - Zhou, Yong
AU - Li, Yinge
AU - Zhang, Yanmin
AU - Zhao, Jianqiu
AU - Hu, Frank B.
AU - Wu, Shouling
AU - Gao, Xiang
N1 - Funding Information:
This work is supported by the National Natural Science Foundation of China (Nos. 81170244, 81170090, and 81773407) and the National Heart, Lung, and Blood Institute of the National Institutes of Health under Award Number K23HL111771 (A.V.). We also received support from the Natural Science Foundation of Shanghai (No. 17ZR1415700). It is registered as a clinical trial under the Kailuan Study (ChiCTR-TNRC-11001489).
Publisher Copyright:
© 2018 AACE.
PY - 2018/9
Y1 - 2018/9
N2 - Objective: We aimed to investigate whether liver steatosis severity affects the risk of developing diabetes in a large cohort study. Methods: We prospectively examined the association in 41,650 Chinese adults with negative hepatitis-B surface antigen who were free of alcohol consumption, diabetes, and liver cirrhosis at baseline. Cox proportional models were used to estimate the risk of diabetes after a mean of 3.6 years of follow-up. Nonalcoholic fatty liver disease (NAFLD) was assessed with hepatic ultrasonography. Elevated alanine transaminase (ALT) was defined as ALT concentrations >19 and >30 U/L in females and males, respectively. Diabetes was defined as a fasting glucose 7.0 mmol/L or treatment with hypoglycemic medication. Results: Liver steatosis severity was significantly associated with higher risks of developing diabetes (adjusted hazard ratio [HR] for severe vs. without NAFLD = 2.66, 95% confidence interval [CI]: 2.17-3.25, P-trend<.001) and impaired fasting glucose (fasting glucose between 5.6 and 6.9 mmol/L, adjusted HR = 1.36, 95% CI: 1.16-1.59, P-trend<.001), as well as a faster increase rate of fasting glucose concentrations (P-trend<.001), during 3.6 years of follow-up. Elevated ALT was also associated with incident diabetes (HR = 1.12, 95% CI: 1.02-1.22), adjusting for NAFLD and other covariates. Conclusion: We observed a dose-response relationship between liver steatosis severity and increased diabetes risk, and ALT may predict incident diabetes independently of NAFLD. (Endocr Pract.
AB - Objective: We aimed to investigate whether liver steatosis severity affects the risk of developing diabetes in a large cohort study. Methods: We prospectively examined the association in 41,650 Chinese adults with negative hepatitis-B surface antigen who were free of alcohol consumption, diabetes, and liver cirrhosis at baseline. Cox proportional models were used to estimate the risk of diabetes after a mean of 3.6 years of follow-up. Nonalcoholic fatty liver disease (NAFLD) was assessed with hepatic ultrasonography. Elevated alanine transaminase (ALT) was defined as ALT concentrations >19 and >30 U/L in females and males, respectively. Diabetes was defined as a fasting glucose 7.0 mmol/L or treatment with hypoglycemic medication. Results: Liver steatosis severity was significantly associated with higher risks of developing diabetes (adjusted hazard ratio [HR] for severe vs. without NAFLD = 2.66, 95% confidence interval [CI]: 2.17-3.25, P-trend<.001) and impaired fasting glucose (fasting glucose between 5.6 and 6.9 mmol/L, adjusted HR = 1.36, 95% CI: 1.16-1.59, P-trend<.001), as well as a faster increase rate of fasting glucose concentrations (P-trend<.001), during 3.6 years of follow-up. Elevated ALT was also associated with incident diabetes (HR = 1.12, 95% CI: 1.02-1.22), adjusting for NAFLD and other covariates. Conclusion: We observed a dose-response relationship between liver steatosis severity and increased diabetes risk, and ALT may predict incident diabetes independently of NAFLD. (Endocr Pract.
UR - http://www.scopus.com/inward/record.url?scp=85054728733&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85054728733&partnerID=8YFLogxK
U2 - 10.4158/EP-2018-0098
DO - 10.4158/EP-2018-0098
M3 - Article
C2 - 29975579
AN - SCOPUS:85054728733
SN - 1530-891X
VL - 24
SP - 823
EP - 832
JO - Endocrine Practice
JF - Endocrine Practice
IS - 9
ER -